Monopar Therapeutics Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Monopar Therapeutics Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	–	–	–	–	$0	$0	$0
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$16.70M	-$16.16M	-$8.83M	-$10.54M	-$9.13M	-$6.51M	-$4.32M	-$3.40M	-$16.60M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$13.72M	-$15.59M	-$8.40M	-$10.52M	-$9.10M	-$6.30M	-$4.22M	-$3.23M	-$16.55M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.85	$-4.11	$-0.61	–	$-0.73	$-0.58	$0.00	$0.00	$-1.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$61.83M	$45.82M	$7.27M	$8.19M	$20.30M	$16.74M	$13.21M	$6.89M	$8.98M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$140.72M	$60.29M	$7.35M	$13.23M	$20.52M	–	$13.35M	$7.32M	$9.93M
Everything the company owes — debt, unpaid bills, and other obligations.	$2.89M	$5.25M	$1.76M	$3.14M	$1.58M	–	$724165	$399551	$311867
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$137.83M	$55.04M	$5.59M	$10.09M	$18.94M	–	$12.63M	$6.92M	$9.62M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$12.20M	-$6.40M	-$7.86M	-$7.23M	$7.32M	-$4.66M	-$3.02M	-$2.89M	-$2.63M